Analyst Ratings for ISIS Pharmaceuticals (ISIS) [Buys]
ISIS Rating Summary
ISIS Price Target Summary
- Highest: $26.00 (Needham & Company)
- Lowest: $7.00 (Jefferies)
- Average: $14.50
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$14.50 (-35.8%)
Avg. $ Target:
$14.50 (-35.8%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 11/9/2012 | Cowen | Upgrade | Outperform (Neutral) |
N/A (N/A) |
7.67 | 22.58 | 194.39% | Details |
| 10/16/2012 | Piper Jaffray | Downgrade | Overweight (N/A) |
10.00 (18.00) |
13.15 | 22.58 | 71.71% | Details |
| 5/22/2012 | Needham & Company » Updated 6/4/2013 |
New Coverage | Buy (N/A) |
26.00 (N/A) |
9.41 | 22.58 | 139.96% | Details |
| 9/8/2011 | BMO Capital | New Coverage | Outperform (N/A) |
15.00 (N/A) |
7.41 | 22.58 | 204.72% | Details |
